At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
CPX-POM - 30 mg/m^2 +7 moredrug
Likely dose
CPX-POM - 30 mg/m^2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors.
In Brief
A Phase 1 clinical trial evaluating CPX-POM - 30 mg/m^2, CPX-POM - 60 mg/m^2, and 6 other interventions for Advanced Solid Tumors. Completed, enrolled 19 participants across 5 sites.
Detailed Summary
This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically- or cytologically-confirmed solid tumor type.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
CollaboratorsCmed Clinical Services
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionMay 2020
TodayJul 2026
First PostedNov 21, 2017
Enrollment StartJan 15, 2018
Primary CompletionMay 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.6 years ago
Interventions
CPX-POM - 30 mg/m^2drug
CPX-POM
CPX-POM - 60 mg/m^2drug
CPX-POM
CPX-POM - 120 mg/m^2drug
CPX-POM
CPX-POM - 240 mg/m^2drug
CPX-POM
CPX-POM - 360 mg/m^2drug
CPX-POM
CPX-POM - 600 mg/m^2drug
CPX-POM
CPX-POM - 900 mg/m^2drug
CPX-POM
CPX-POM - 1200 mg/m^2drug
CPX-POM